Nab-paclitaxel /m^2
Phase 2Small molecule
Nab-paclitaxel /m^2 is one of 118 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.
3
Indications
5
Total Trials
3
Active Trials
117
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Lenvima
EisaiPreclinical
Vizimpro
PfizerPreclinical
Nab-paclitaxel /m^2
CCorcept Therapeutics
Phase 2
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
REGN2810
RegeneronPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Primary Peritoneal1 trial
Treatment1 trial
Adenocarcinoma1 trial
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Completed·—·Phase 2·NCT03283761·39 enrolled
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nab-paclitaxel /m^2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCorcept Therapeutics